Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17407791 | 1.00 | CPB1 (0.51) | CPB1CYP2C19CYP1A2TSHRALDH1A1 | |
| SCHEMBL6406962 | 0.92 | FFAR4 (0.49) | CPB1CYP2C19CYP1A2TSHRALDH1A1 | |
| SCHEMBL19730184 | 0.90 | CPB1 (0.46) | CPB1CYP2C19CYP1A2TSHRALDH1A1 | |
| SCHEMBL19714832 | 0.90 | CPB1 (0.46) | CPB1CYP2C19CYP1A2TSHRALDH1A1 | |
| SCHEMBL6406569 | 0.87 | HTT (0.49) | CPB1ALDH1A1CYP3A4POLBFFAR4 | |
| SCHEMBL23970385 | 0.85 | CA1 (0.49) | TSHRALDH1A1FFAR4AGTR2 | |
| SCHEMBL15927893 | 0.85 | CA1 (0.49) | TSHRALDH1A1FFAR4AGTR2 | |
| SCHEMBL23970542 | 0.85 | CA1 (0.49) | TSHRALDH1A1FFAR4AGTR2 | |
| SCHEMBL18630954 | 0.85 | CA1 (0.49) | TSHRALDH1A1FFAR4AGTR2 | |
| SCHEMBL5925105 | 0.85 | CA1 (0.49) | TSHRALDH1A1FFAR4AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288526-A1 | Process for production of 2-(hydroxymethyl)cyclo-propanecarboxylic acids | SUMITOMO CHEMICAL COMPAY LIMTED (JP) | 2005-12-29 | — | — | US | disclosed |
| CN-1681767-A | Method for manufacturing 2-(hydroxymethyl) cyclopropane carboxylic acid compound | SUMITOMO CHEMICAL CO (JP) | 2005-10-12 | — | — | CN | disclosed |
| EP-1538141-A1 | PROCESS FOR PRODUCTION OF 2-(HYDROXYMETHYL)CYCLO- PROPANECARBOXYLIC ACIDS | Sumitomo Chemical Company, Limited (JP) | 2005-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288526-A1 | Process for production of 2-(hydroxymethyl)cyclo-propanecarboxylic acids | GRHPR, PCCA, C5 | CPB1 1574/4885CYP2C19 160/4885CYP1A2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.